Vaccine-immunotherapy combination extends RFS in high-risk melanoma

The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.
The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.
“This randomized trial involved patients who had surgery to remove melanoma and were at high risk [for] the disease returning,” Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Perlmutter

The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.
The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.
“This randomized trial involved patients who had surgery to remove melanoma and were at high risk [for] the disease returning,” Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Perlmutter